Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

Abstract

Posterior segment eye diseases present a challenge in treatment due to the complex structures in the eye that serve as robust static and dynamic barriers, limiting the penetration, residence time, and bioavailability of topical and intraocular medications. This hinders effective treatment and requires frequent dosing, such as the regular use of eye drops or visits to the ophthalmologist for intravitreal injections, to manage the disease. Moreover, the drugs must be biodegradable to minimize toxicity and adverse reactions, as well as small enough to not affect the visual axis. The development of biodegradable nano-based drug delivery systems (DDSs) can be the solution to these challenges. First, they can stay in ocular tissues for longer periods of time, reducing the frequency of drug administration. Second, they can pass through ocular barriers, offering higher bioavailability to targeted tissues that are otherwise inaccessible. Third, they can be made up of polymers that are biodegradable and nanosized. Hence, therapeutic innovations in biodegradable nanosized DDS have been widely explored for ophthalmic drug delivery applications. In this review, we will present a concise overview of DDSs utilized in the treatment of ocular diseases. We will then examine the current therapeutic challenges faced in the management of posterior segment diseases and explore how various types of biodegradable nanocarriers can enhance our therapeutic arsenal. A literature review of the pre-clinical and clinical studies published between 2017 and 2023 was conducted. Through the advances in biodegradable materials, combined with a better understanding of ocular pharmacology, the nano-based DDSs have rapidly evolved, showing great promise to overcome challenges currently encountered by clinicians.

Options for Topical Treatment of Oxidative Eye Diseases with a Special Focus on Retinopathies

“…This approach has shown potential for treating various ocular conditions, including glaucoma, macular degeneration, diabetic retinopathy, and other inflammatory eye diseases [ 127 ]. As research in nanotechnology continues to advance, the development of innovative nanocarrier-based formulations holds great promise for improving the efficacy and precision of ocular drug delivery [ 128 ].…”

Hydrogels in Ophthalmology: Novel Strategies for Overcoming Therapeutic Challenges

“…Although some drugs can navigate into the aqueous humor via the transcorneal route, they often fail to reach the posterior segments of the eye at therapeutic concentrations due to the vitreous barriers [ 1 ].…”

“…The intricate anatomical and physiological design of the human eye introduces distinct challenges, both pharmacologically and surgically, when managing various ocular pathologies [ 1 ]. Over recent years, there has been a concerted effort in the ophthalmological community to improve the delivery of therapeutic agents and enhance surgical interventions.…”

Eye Drop with Fas-Blocking Peptide Attenuates Age-Related Macular Degeneration

“…Although wet AMD can be treated with FDA-approved intravitreal anti-vascular endothelial growth factor (VEGF) drug injections, such as Lucentis and Eylea, these treatments are not universally responsive, are invasive, and are associated with potential side effects [ 5 , 6 , 7 , 8 ]. To address the challenges of intravitreal injection, alternative drug delivery routes, such as topical administration, have been investigated for AMD [ 9 , 10 , 11 ]. Unfortunately, ongoing research has yet to yield a viable treatment option for dry AMD, prompting the use of symptomatic approaches involving antioxidants and vitamins [ 5 , 12 ].…”